IP Library Granted Patent US 8,273,791
Granted Patent B2
US 8,273,791 · App. 12/331,781 · Granted Sep 25, 2012

Compositions, kits and regimens for the treatment of skin, especially décolletage

Assignee: JR Chem, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,273,791
App. No.
12/331,781
Granted
Sep 25, 2012
Kind
B2
Abstract

Compositions, kits and regimens for treatment of damaged skin, especially décolletage, include application of a retinoid, hydroquinone or hydroquinone derivatives, and a composition containing a multi-metal complex.

Claims (32)

1. A method of treating skin comprising:

administering to an area of skin a first treatment and, after a predetermined period of time, a second treatment,

the first treatment comprising topically applying a retinoid, a hydroquinone, and a multi-metal complex;

the second treatment comprising topically applying a hydroquinone and a multi-metal complex

wherein the multi-metal complex employed in the first treatment and in the second treatment comprises a central malonate unit, wherein the central malonate unit bridges one or more copper molecules and one or more zinc molecules by coordinate bonding.

2. The method according to claim 1 , further comprising the step of waiting at least four hours between the first treatment and the second treatment.

3. The method according to claim 1 , wherein the first treatment occurs in the morning.

4. The method according to claim 3 , wherein the second treatment occurs in the evening.

5. The method according to claim 1 , wherein the first treatment occurs in the evening.

6. The method according to claim 1 , further comprising sequentially applying the retinoid, the hydroquinone, and the multi-metal complex of the first treatment.

7. The method according to claim 1 , further comprising pre-mixing the retinoid and the hydroquinone of the first treatment substantially immediately prior to administering the first treatment to the area of skin.

8. A method comprising:

pre-mixing a retinoid with a hydroquinone-containing composition to form a pre-mixed formulation;

applying the pre-mixed formulation to the skin; and

applying a composition comprising a multi-metal complex to the skin

wherein the multi-metal complex comprises a central malonate unit, wherein the central malonate unit bridges one or more copper molecules and one or more zinc molecules by coordinate bonding.

9. The method according to claim 8 , wherein the pre-mixed formulation is applied to the skin prior to the composition comprising the multi-metal complex.

10. A method of treating skin comprising:

topically applying a retinoid and a hydroquinone to an area of non-facial skin; and

topically applying a composition comprising at least one multi-metal complex to the area of non-facial skin previously treated with retinoid and hydroquinone, wherein the multi-metal complex comprises a central malonate unit, wherein the central malonate unit bridges one or more copper molecules and one or more zinc molecules by coordinate bonding.

11. The method according to claim 10 , wherein the area of non-facial skin is the décolletage.

12. The method according to claim 10 , wherein the retinoid and hydroquinone are sequentially applied to the area of non-facial skin.

13. The method according to claim 10 , wherein the retinoid and hydroquinone are simultaneously applied to the area of non-facial skin.

14. The method according to claim 10 , wherein the retinoid is retinol.

15. The method according to claim 10 , wherein the retinoid is tretinoin.

16. The method according to claim 10 , wherein the hydroquinone is arbutin.

17. A method of treating skin comprising:

topically applying a retinoid and a hydroquinone to an area of non-facial skin; and

topically applying a composition comprising at least one multi-metal complex to the area of non-facial skin previously treated with retinoid and hydroquinone, wherein the multi-metal complex comprises a central unit, wherein the central unit is derived from at least one compound selected from polycarboxylic acids and amino acids having at least two carboxylic acid groups and the center unit bridges one or more copper molecules and one or more zinc molecules by coordinate bonding.

18. A method of treating skin comprising:

topically applying a retinoid and a hydroquinone to an area of non-facial skin; and

topically applying a composition comprising at least one multi-metal complex to the area of non-facial skin previously treated with retinoid and hydroquinone, wherein the multi-metal complex comprises a reaction product of a compound having two or more carboxylic acid groups with basic salts of two or more coordination elements selected from one or more of copper, silver, gold, aluminum, scandium, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, gallium, yttrium, zirconium, niobium, molybdenum, technetium, ruthenium, rhodium, palladium, silver, cadmium, and indium, wherein the two or more coordination elements are joined to a central unit derived from the compound having two or more carboxylic acid groups.

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST Recorded Mar 21, 2025
From: JPMORGAN CHASE BANK, N.A.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 070592/0979 →
SECURITY INTEREST Recorded Aug 1, 2022
From: OBAGI COSMECEUTICALS LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060690/0148 →
RELEASE OF SECURITY INTEREST Recorded Jul 29, 2022
From: TCW ASSET MANAGEMENT COMPANY LLC
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 060668/0771 →
RELEASE OF SECURITY INTEREST Recorded Mar 19, 2021
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 055652/0735 →
SECURITY INTEREST Recorded Mar 16, 2021
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 055613/0083 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 13, 2018
From: OBAGI COSMECEUTICALS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 047873/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: OBAGI MEDICAL PRODUCTS, INC.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 044829/0092 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BARCLAYS BANK PLC
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 044750/0475 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BANK OF NEW YORK MELLON
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 044750/0506 →
SECURITY INTEREST Recorded Jul 19, 2017
From: OBAGI MEDICAL PRODUCTS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0718 →
SECURITY INTEREST Recorded Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA); VALEANT PHARMACEUTICALS NORTH AMERICA LLC; VALEANT PHARMACEUTICALS IRELAND
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2014
From: JR CHEM, LLC
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 032045/0367 →
RELEASE OF SECURITY INTEREST Recorded May 30, 2013
From: COMERICA BANK, A TEXAS BANKING ASSOCIATION, AS AGENT
To: OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.
Reel/Frame 030518/0552 →
SECURITY AGREEMENT Recorded Feb 19, 2009
From: OMP, INC.; OBAGI MEDICAL PRODUCTS, INC.
To: COMERICA BANK, AS AGENT
Reel/Frame 022280/0748 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2009
From: RAMIREZ, JOSE R; FARYNIARZ, JOSEPH R.
To: JR CHEM, LLC
Reel/Frame 022265/0381 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2008
From: RAMIREZ, JOSE E.; FARYNIARZ, JOSEPH R.
To: JR CHEM, LLC
Reel/Frame 021955/0209 →
Continuity (2)
Provisional Application 61019047 · Jan 4, 2008
Related Publication 20090176876A1 · Jul 9, 2009